Full Press Release Details
INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE
Call Scheduled for Today at 4:30 p.m. Eastern Time
NJ - March 29, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the
fourth quarter and full year ended December 31, 2021 and provided an update on recent business developments.
Recent Corporate Highlights:
Dr. Matt David, CorMedix
interim CEO, commented, "We are very pleased to share the updates this week regarding the FDA acceptance for filing of our DefenCath
resubmission. The CorMedix team is working hard as we continue to lay the groundwork for a potential commercial launch of DefenCath following
its anticipated approval. Catheter related bloodstream infections are a frequent occurrence in patients receiving hemodialysis via central
venous catheters and are associated with significant morbidity and mortality. We look forward to providing updates as we aim to deliver
on our commitment to these patients."
4th Quarter 2021 Financial Highlights
For the fourth quarter
of 2021, CorMedix recorded a net loss of $7.8 million, or $0.20 per share, compared with a net loss of $6.1 million, or $0.19 per share,
in the fourth quarter of 2020. The increase in net loss in the fourth quarter of 2021 compared with 2020 was primarily driven by increases
in costs related to the manufacturing of DefenCath prior to its potential marketing approval and non-cash charges for stock-based compensation.
Operating expenses during the fourth quarter of 2021 were $7.8 million, compared with $6.1 million in the fourth quarter of 2020, an increase
of approximately $1.7 million.
Full Year 2021 Financial
For the year ended December
31, 2021, CorMedix recorded a net loss of $28.2 million, or $0.75 per share, compared with a net loss during the year ended December 31,
2020 of $22.0 million, or $0.77 per share. The increase in net loss was driven primarily by increases in operating expenses.
Operating expenses during
the year ended December 31, 2021 amounted to $29.5 million compared with $27.3 million during the comparable period in 2020, an increase
of $2.2 million, or 8%, due to a 18% increase in SG&A expense, offset by a 2% decrease in R&D expense.
Total cash on hand and
short-term investments as of December 31, 2021 amounted to $65.5 million, excluding restricted cash of $0.2 million. Including approximately
$3.0 million in net proceeds from ATM issuances during 1Q of 2022, CorMedix has December 31, 2021 pro forma cash and equivalents and short-term
investments of $68.5 million. The Company believes that it has sufficient resources to fund operations through the first half of 2023.
Conference Call Information
The management team of
CorMedix will host a conference call and webcast today, March 29, 2022, at 4:30 PM Eastern Time, to discuss recent corporate developments
and financial results. Call details and dial-in information is as follows:
Tuesday, March 29th @ 4:30pm ET
Domestic: 1-877-423-9813
International: 1-201-689-8573
Conference ID: 13727363
Webcast: Webcast Link
CorMedix Inc. is a biopharmaceutical
company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory
diseases. The company is focused on developing its lead product DefenCath , a novel, antibacterial and antifungal solution designed
to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing
chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the
original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. QIDP provides
for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval
of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis
when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The company received
a Complete Response Letter from FDA stating that the original NDA could not be approved until satisfactory resolution of deficiencies
at the contract manufacturing facility, including in-process controls for the filling operation. We believe the deficiencies have been
addressed in the resubmitted NDA that has been accepted for filing by FDA. CorMedix also intends to develop DefenCath as a catheter lock
solution for use in other patient populations. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical
devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to
develop taurolidine-based therapies for rare pediatric cancers. Neutrolin is CE Marked and marketed in Europe and other territories
as a medical device. For more information, visit: www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial
position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual
results may differ materially from projections or estimates due to a variety of important factors, including: the results of our discussions
with the FDA regarding the DefenCath development path for marketing authorization; the resources needed to secure approval of the new
drug application for DefenCath from the FDA; our ability to address the deficiencies identified at our CMO in connection with the manufacture
of DefenCath; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources and the impact
on current, planned or future research, including the continued development of DefenCath/Neutrolin and research for additional uses for
taurolidine; obtaining additional financing to support CorMedix's research and development and clinical activities and operations;
preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials;
and the ability to retain and hire necessary personnel to staff our operations appropriately. We continue to assess to what extent the
uncertainty surrounding the Coronavirus pandemic may impact our business and operations. These and other risks are described in greater
detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov
or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking
statements, except as required by law.
CORMEDIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)
| For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue: | ||||||||||||||||
| Net sales | $ | 56,397 | $ | 55,713 | $ | 190,936 | $ | 239,231 | ||||||||
| Cost of sales | (48,007 | ) | (57,233 | ) | (148,938 | ) | (204,846 | ) | ||||||||
| Gross profit (loss) | 8,390 | (1,520 | ) | 41,998 | 34,385 | |||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | (3,235,219 | ) | (2,294,430 | ) | (13,132,982 | ) | (13,377,193 | ) | ||||||||
| Selling, general and administrative | (4,553,092 | ) | (3,788,690 | ) | (16,346,601 | ) | (13,877,944 | ) | ||||||||
| Total Operating Expenses | (7,788,311 | ) | (6,083,120 | ) | (29,479,583 | ) | (27,255,137 | ) | ||||||||
| Income (loss) From Operations | (7,779,921 | ) | (6,084,640 | ) | (29,437,585 | ) | (27,220,752 | ) | ||||||||
| Other Income (Expense): | ||||||||||||||||
| Interest income | 4,367 | 2,940 | 14,403 | 116,065 | ||||||||||||
| Foreign exchange transaction (loss) gain | (10,055 | ) | 76 | (21,287 | ) | (59,165 | ) | |||||||||
| Interest expense | (5,378 | ) | (5,322 | ) | (15,943 | ) | (33,226 | ) | ||||||||
| Total Other (Expense) Income | (11,066 | ) | (2,306 | ) | (22,827 | ) | 23,674 | |||||||||
| Net Loss Before Income Taxes | (7,790,987 | ) | (6,086,946 | ) | (29,460,412 | ) | (27,197,078 | ) | ||||||||
| Tax benefit | - | - | 1,250,186 | 5,169,395 | ||||||||||||
| Net Loss | (7,790,987 | ) | (6,086,946 | ) | (28,210,226 | ) | (22,027,683 | ) | ||||||||
| Other Comprehensive (Loss) Income | (8,372 | ) | 2,347 | (14,876 | ) | 4,749 | ||||||||||
| Comprehensive Loss | $ | (7,799,359 | ) | $ | (6,084,599 | ) | $ | (28,225,102 | ) | $ | (22,022,934 | ) | ||||
| Net Income (Loss) Per Common Share - Basic and Diluted | $ | (0.20 | ) | $ | (0.19 | ) | $ | (0.75 | ) | $ | (0.77 | ) | ||||
| Weighted Average Common Shares Outstanding - Basic and Diluted | 38,113,514 | 32,402,336 | 37,666,081 | 28,561,963 |
CORMEDIX INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| December 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Cash, cash equivalents and restricted cash | $ | 53,551,277 | $ | 42,096,783 | ||||
| Short-term investments | $ | 12,149,003 | $ | 4,444,072 | ||||
| Total Assets | $ | 68,945,576 | $ | 49,308,303 | ||||
| Total Liabilities | $ | 6,147,509 | $ | 5,085,291 | ||||
| Accumulated deficit | $ | (245,659,081 | ) | $ | (217,448,855 | ) | ||
| Total Stockholders' Equity | $ | 62,798,067 | $ | 44,223,012 |
CORMEDIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||||||||
| 2021 | 2020 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net loss | $ | (28,210,226 | ) | $ | (22,027,683 | ) | ||
| Net cash used in operating activities | (21,155,223 | ) | (21,967,638 | ) | ||||
| Cash Flows Used In Investing Activities: | ||||||||
| Net cash (provided by) used in investing activities | (9,134,915 | ) | 7,426,176 | |||||
| Cash Flows From Financing Activities: | ||||||||
| Net cash provided by financing activities | 41,757,551 | 40,099,866 | ||||||
| Foreign exchange effects on cash | (12,919 | ) | 13,192 | |||||
| Net Increase (Decrease) in Cash and Cash Equivalents | 11,454,494 | 25,571,596 | ||||||
| Cash and Cash Equivalents and Restricted Cash - Beginning of Period | 42,096,783 | 16,525,187 | ||||||
| Cash -and Cash Equivalents and Restricted Cash - End of Period | $ | 53,551,277 | $ | 42,096,783 |